The Silent Epidemic Behind Vision Decline in Adults Over 60
A message from Klaris. This article is produced by Klaris and recommends Klaris Visual Performance Complex. It was medically reviewed for accuracy by Dr. Elena Markovic, MD.


If you are over 60 and reading this on a phone, something in this article applies to you.
You weren't supposed to be staring at a backlit screen for six hours a day at 68 years old. Your eyes didn't evolve for it. Nobody's did. But the generation now in their 60s and 70s is the first to live through a full decade, sometimes two, of daily high-exposure screen time, on top of all the normal age-related changes happening inside the retina.
That combination is producing a pattern I wasn't seeing ten years ago. Patients come in complaining about "tired eyes" that no amount of rest seems to fix, a weird dullness to colors, halos around headlights at night, and a slow creeping loss of reading stamina. They assume it's just age.
It isn't just age. It's age plus screens plus a vitamin gap most people don't know exists.
1.What I'm seeing in the chair that I wasn't seeing ten years ago
The 60+ patients walking into my exam room today look different on paper than they did a decade ago. Their intraocular pressures are fine. Their prescriptions have barely shifted. Their cataracts are graded mild. By the old metrics, they're aging well.
But their macular pigment readings are lower than expected for their age. Their contrast sensitivity is trending toward what I used to see in patients five to ten years older. The symptoms they describe are almost uniform: late-day eye ache, difficulty switching focus from a phone to a dashboard, an unexplained reluctance to drive after sunset.

Nobody tested for this twenty years ago because nobody needed to. The exposure didn't exist. The 60+ patient in 2026 has been a daily screen user since her mid-40s. That is fifteen to twenty years of retinal tissue absorbing high-energy blue light, on top of all the normal changes of age.
2.What 15 years of daily screens asks of a 60-year-old eye
The back of your eye has a small area called the macula. Inside it sits a yellow pigment layer that does three jobs: it absorbs high-energy blue light before it reaches your photoreceptors, it quenches oxidative stress inside the tissue, and it sharpens contrast so edges stay crisp.
The pigment is made of three carotenoids your body cannot manufacture: lutein, zeaxanthin, and meso-zeaxanthin. Two things have been happening to this pigment at the same time.
First, it thins with age. Macular pigment optical density tends to decline gradually through adult life, and lower readings are common in older adults.
Second, it's under heavier load than ever. Screens emit a concentrated band of high-energy blue light, an active area of eye research for its role in retinal stress. Most UV is absorbed by the lens before it reaches the back of the eye, but visible blue light reaches the retina - and every hour of screen time is an hour your macular pigment is doing the filtering.
For someone who has been doing 4 to 8 hours a day on phones, tablets, and computers for the last 10 to 15 years, the math is ugly. You're losing pigment to age, and a typical diet delivers far less of the three carotenoids than the doses used in studies.

Someone a decade older who grew up before screens may have stronger functional vision, and cumulative exposure is one possible explanation researchers are studying.
3.The three missing ingredients
When I review what my 60+ patients are already taking, it's usually a well-known eye formula built around the original AREDS2 blueprint. That formula was designed in the early 2010s for a different purpose: slowing progression in people with existing intermediate macular degeneration. It was a clinical trial tool, not a digital-age maintenance formula.
There are three ingredients that the research has moved on to since, and that most shelf eye vitamins still don't include.
Meso-zeaxanthin: protects the center of your vision
Lutein and zeaxanthin cover the outer and middle zones of the macula. But the very center, the fovea, is coated almost entirely by meso-zeaxanthin. Without it, your foveal center, the part responsible for the sharpest detail, stays thinly protected. Most eye vitamins don't include it. The Klaris Supplement includes 10 mg.

Astaxanthin: helps your focusing muscle relax
Behind the lens sits a ring of muscle called the ciliary body. When you hold a phone six inches from your face for thirty minutes, that ring is under continuous contraction. Extend that across years and you get the late-afternoon fatigue pattern of blurred reading and dry, heavy eyes.

Astaxanthin, a carotenoid from red microalgae, has been shown in clinical trials to reduce visible accommodative fatigue. Most shelf eye vitamins don't include it. The Klaris Supplement includes 4 mg.
Active-form B-vitamins: what your optic nerve actually uses
The B-vitamins (B6, folate, B12) keep the optic nerve signal crisp. But most multivitamins and eye vitamins use the inactive forms, which require a conversion step in the liver. Many adults carry a common gene variant (MTHFR) that makes that conversion less efficient. The Klaris Supplement uses the active, already-converted forms.
4.What rebuilding looks like
These are general patterns; individual results vary, and a supplement is not a treatment.
None of this is inevitable. The pigment layer rebuilds when it's fed the right carotenoids in the right doses. Screen exposure is cumulative, but macular defense is renewable.
Day 1 to Week 1. The active B-vitamins and astaxanthin start absorbing within hours. Most patients notice the late-afternoon heavy-eye feeling ease first.
Week 1 to Week 3. Screen discomfort drops. Readers feel they can stay on-page longer. Night glare starts to soften.
Month 1 to Month 2. Macular pigment rebuild is underway. Internal light filtering is gradually strengthening.
Month 3 to Month 4. Sharper acuity. Colors look cleaner. Night driving is noticeably easier.
Month 5 to Month 6. Full protective effect. You're no longer rebuilding, you're defending.

5.What is in the Klaris Supplement
Eleven ingredients at clinical doses, plant-based, no beta-carotene. The full carotenoid stack (lutein, zeaxanthin, meso-zeaxanthin, astaxanthin) sits at 26 mg total, the active B-complex covers the optic nerve pathway, and zinc citrate replaces the harsher zinc oxide used in older formulas.
Two capsules a day, with food. A 60-capsule bottle is a 30-day supply.

6.Who this is for
If any of the following describe you, the Klaris Supplement is built for you:
- You're over 60 and have been on phones, computers, or tablets for four or more hours a day for the last decade.
- Your reading stamina is shorter than it used to be, especially after 4 PM.
- You've started preferring lamps directly over the page.
- Headlights at night are starting to bloom or halo more than you remember.
- You've already looked at the eye vitamin on your counter and wondered if it's doing enough.
7.Start the rebuild
Macular pigment can be rebuilt with the right nutrients, which studies link to better contrast and low-light comfort over time. But it has to be fed, and the three ingredients that matter most for a 60+ screen user (meso-zeaxanthin, astaxanthin, and active-form B-vitamins) are not in most of what's on the shelf.
The Klaris Supplement is. Two capsules a day. A 30-day bottle. A six-month rebuild timeline.

This article is for general informational purposes only and is not medical advice. Do not start any supplement program without consulting your physician, optometrist, or ophthalmologist. Statements about Klaris have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
- Bone RA, Landrum JT. Heterochromatic flicker photometry. Arch Biochem Biophys. 2004.
- Stringham JM, Hammond BR. Macular pigment and visual performance under glare conditions. Optom Vis Sci. 2008.
- Sasaki M, et al. Astaxanthin reduces accommodative fatigue. J Clin Ther Med. 2006.
- Christen WG, et al. Folic acid, B6, and B12 in combination and age-related macular degeneration. Arch Intern Med. 2009.
- Loughman J, et al. The impact of macular pigment augmentation on visual performance. Vision Res. 2012.